Pharmexa Loses Bid To Restore Broad Patent Claims
Geron Corp., a rival biotech company, said Tuesday the Technical Board of Appeal of the EPO invalidated the claims of a European patent filed by Pharmexa in 2003, finding that they were overbroad and infringed claims patented by Geron.
The Pharmexa patent covered the use of telomerase peptides and nucleic acids for cancer immunotherapy.
Geron, based in Menlo...
To view the full article, register now.